BPTSY (Biophytis) Total Liabilities: $16.66 Mil (As of Jun. 2025)


BPTSY Biophytis SA BPTSY
18 GF Score
Price $0.25
! 5 Warning Signs
View Full Analysis

What is Biophytis Total Liabilities?

Biophytis BPTSY 18 Total Liabilities is $16.66 Mil as of Jun. 2025. GuruFocus rates BPTSY with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Biophytis's Total Liabilities for the quarter that ended in Jun. 2025 was $16.66 Mil.

Biophytis's quarterly Total Liabilities increased from Jun. 2024 ($16.29 Mil) to Dec. 2024 ($17.39 Mil) but then declined from Dec. 2024 ($17.39 Mil) to Jun. 2025 ($16.66 Mil).

Biophytis's annual Total Liabilities declined from Dec. 2022 ($25.32 Mil) to Dec. 2023 ($17.28 Mil) but then increased from Dec. 2023 ($17.28 Mil) to Dec. 2024 ($17.39 Mil).

Biophytis Total Liabilities Historical Data

* Premium members only.

The historical data trend for Biophytis's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biophytis Total Liabilities Chart

Biophytis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.34 32.85 25.32 17.28 17.39

Biophytis Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.47 17.28 16.29 17.39 16.66
BPTSY
18GF Score
Biophytis SA BPTSY
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biophytis Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biophytis's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=16.343+(0.088+0.705
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.25+0)
=17.39

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=7.227--10.159
=17.39

Biophytis's Total Liabilities for the quarter that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.668+(3.128+0.606
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.255+0)
=16.66

Total Liabilities=Total Assets (Q: Jun. 2025 )-Total Equity (Q: Jun. 2025 )
=7.639--9.018
=16.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $16.66 Mil mean?
Biophytis (BPTSY) has a Total Liabilities of $16.66 Mil as of Jun. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Biophytis and its competitors.
Is Biophytis' Total Liabilities too high?
Biophytis' current Total Liabilities is $16.66 Mil. Overall, Biophytis has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biophytis' Total Liabilities compare to VRTX and REGN?
Biophytis' Total Liabilities of $16.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Biophytis and its competitors. Biophytis's current Total Liabilities is $16.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biophytis stock overvalued right now?
Biophytis (BPTSY) has a current Total Liabilities of $16.66 Mil. The current Total Liabilities is $16.66 Mil. Biophytis' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Biophytis (BPTSY), the current Total Liabilities is $16.66 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biophytis Business Description

Address BC 9, Batiment A 4eme etage, 4 Place Jussieu, Sorbonne University, Paris, FRA, 75005
Biophytis SA is a France-based clinical-stage biotechnology company engaged in the development of drug candidates for the treatment of age-related and respiratory diseases. The company focuses on therapies that target degenerative processes associated with aging and improve functional outcomes. Its drug candidate, BIO101, is an orally administered small molecule under development for neuromuscular and respiratory indications, including sarcopenia, Duchenne muscular dystrophy (DMD), and respiratory failure.
18GF Score

Get the complete analysis for BPTSY

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price